LNAI News & Events

Lunai Bioworks and Geneial, a precision medicine data infrastructure and patient engagement company, announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent, or LOI, with Geneial to pursue a strategic collaboration in rare neurological disorders. The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships. Under the proposed collaboration, BioSymetrics and Geneial plan to: integrate and standardize patient-led rare disease datasets; identify defined patient subgroups for clinical development; generate actionable insights to support therapeutic programs; enable the activation of trial-ready cohorts for pharma and biotech engagement. The companies expect to pursue commercial partnerships enabled by these efforts. The initial focus will include select rare neurodevelopmental disorders, with the goal of building scalable programs that can expand over time. The LOI is non-binding.

Lunai Bioworks has executed a binding $20M strategic transaction to acquire blood-brain barrier, or BBB, delivery technology and central nervous system, or CNS, Alzheimer's drug assets from the Clemann Group, SAS or its assignee. The transaction is structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share, subject to a 19.9% beneficial ownership limitation. The transaction aims to strengthen Lunai's CNS Alzheimer's pipeline by pairing biological target identification with a proven delivery method and expand the company's ability to develop next-generation treatments across a broad range of CNS disorders where traditional drugs struggle to penetrate the brain effectively, offering the potential for improved safety and efficacy.

Lunai Bioworks announced the formation of a national consortium designed to accelerate the discovery and development of chemical countermeasures for emerging battlefield and terrorism threats. The Pathfinder Consortium, a national academic-industry alliance designed to consolidate historically siloed U.S. chemical warfare preparedness resources into a unified, execution-ready infrastructure capable of accelerating medical countermeasure development to approximately three years. Unlike traditional pharmaceutical development cycles, chemical countermeasures can follow accelerated regulatory pathways. The Pathfinder model is structured to: Demonstrate efficacy in yeast and cell-based systems Validate therapeutic effects in FDA-recognized zebrafish models Complete two confirmatory animal studies Conduct a 50-person Phase I safety study The full process can be completed in approximately 36 months. In many cases, existing FDA-approved drugs may be repurposed, potentially reducing timelines even further. Pathfinder includes collaboration with nationally recognized experts, including: Dr. Calum MacRae, Brigham and Women's Hospital and Harvard Medical School; Dr. Vik Bebarta, Colonel, U.S. Air Force Reserve; University of Colorado; Dr. Randall Peterson, University of Utah; Dr. Vincent Jo Davidson, Purdue University.

Lunai Bioworks announced the issuance of a U.S. patent titled "Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions." The newly issued patent protects the foundational first step of Lunai's proprietary closed-loop disease reverse engineering platform, multimodal data standardization and structural bias removal prior to predictive modeling. Lunai's patented architecture systematically detects, standardizes, and removes structural bias across multimodal inputs before downstream artificial intelligence modeling begins. By protecting this core data layer, Lunai aims to strengthen its ability to accurately identify biologically coherent patient subtypes and trace those subtypes to the gene networks most strongly associated with each disease type.